FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. by Jauniaux, E et al.
1 
 
FIGO GUIDELINES 
FIGO consensus guidelines on placenta accreta spectrum disorders: 
Prenatal diagnosis and screening★,§ 
 
Eric Jauniaux 1, Amar Bhide 2, Anne Kennedy 3, Paula Woodward 3, Corrine 
Hubinont 4, Sally Collins 5,6; for the FIGO Placenta Accreta Diagnosis and 
Management Expert Consensus Panel* 
 
1 EGA Institute for Women’s Health, Faculty of Population Health Sciences, 
University College London, London, UK 
2 Fetal Medicine Unit, Department of Obstetrics and Gynecology, St George's 
Hospital, London, UK 
3 Department of Radiology and Imaging Sciences, University of Utah Health 
Sciences Center, Salt Lake City, UT, USA 
4 Department of Obstetrics, Saint Luc University Hospital, University of 
Louvain, Brussels, Belgium 
5 Nuffield Department of Obstetrics and Gynecology, University of Oxford, 
John Radcliffe Hospital, Oxford, UK 
6 Fetal Medicine Unit, John Radcliffe Hospital, Oxford, UK 
 
★ Developed by the FIGO Safe Motherhood and Newborn Health Committee; 
coordinated by Eric Jauniaux, lead developer and corresponding author: 
e.jauniaux@ucl.ac.uk 
§The views expressed in this document reflect the opinion of the individuals 
and not necessarily those of the institutions that they represent. 
2 
 
* Consensus panel: Greg Duncombe (Australia and New Zealand), Philipp 
Klaritsch (Germany), Frédéric Chantraine (Belgium), John Kingdom (Canada), 
Lene Grønbeck (Denmark), Kristiina Rull (Estonia), Balkachew Nigatu 
(Ethiopia), Minna Tikkanen (Finland), Loïc Sentilhes (France), Tengiz Asatiani 
(Georgia), Wing-Cheong Leung (Hong Kong), Taghreed AIhaidari (Iraq), 
Donal Brennan (Ireland), Eiji Kondoh (Japan), Jeong-In Yang (South Korea), 
Muhieddine Seoud (Lebanon), Ravindran Jegasothy (Malaysia), Salvador 
Espino y Sosa (Mexico), Benoit Jacod (Netherlands), Francesco D’Antonio 
(Norway), Nusrat Shah (Pakistan), Dorota Bomba-Opon (Poland), Diogo 
Ayres-de-Campos (Portugal), Katarina Jeremic (Serbia), Tan Lay Kok 
(Singapore), Priya Soma-Pillay (South Africa), Nataša Tul Mandić (Slovenia), 
Pelle Lindqvist (Sweden), Thora Berglind Arnadottir (Sweden), Irene Hoesli 
(Switzerland), Unnop Jaisamrarn (Thailand), Amal Al Mulla (United Arab 
Emirates), Stephen Robson (UK), Rafael Cortez (Venezuela). 
  
3 
 
1. Introduction 
Recent population studies have shown that placenta accreta spectrum (PAS) 
disorders remain undiagnosed before delivery in half [1,2] to two-thirds of 
cases [3]. In a series from specialist diagnostic units in the USA, around one-
third of cases of PAS disorders were not diagnosed during pregnancy [4]. 
Maternal mortality and morbidity are reduced when women with PAS 
disorders, particularly the invasive forms—placenta increta or percreta—
deliver in a center of excellence by a multidisciplinary care team with 
experience in managing the surgical risks and perioperative challenges 
presented by these disorders [5–8]. Transfer to a center of excellence, 
however, relies on both recognition of the women at risk of PAS disorders and 
on accurate prenatal diagnosis. 
 
Current prenatal diagnosis rests on subjective interpretation of “typical” 
sonographic findings or signs with two-dimensional (2D) grey-scale and color 
Doppler imaging. Many signs have been reported in the literature with varying 
descriptions as to their sensitivity and specificity [9]. The published literature is 
difficult to interpret because of several problems in the definition, terminology, 
and diagnosis of this disorder [10]. To improve consistency and allow 
appropriate comparison of different imaging markers, panels of experts have 
published consensus statements that aim to standardize the descriptions and 
minimum requirements for an ultrasound scan to diagnose PAS disorders 
[11,12]. 
 
Magnetic resonance imaging (MRI), although widely employed, has yet to 
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clearly demonstrate a significant improvement in management or pregnancy 
outcomes [13]. MRI is expensive and requires expertise that is rarely available 
in most low-income countries and many medium-income countries. MRI is 
currently only recommended as an adjunct to ultrasound imaging by many 
professional bodies throughout the world including the Royal College of 
Obstetricians and Gynaecologists (RCOG) in the UK [14]. Irrespective of the 
imaging modality used, prenatal diagnosis of PAS disorders remains 
subjective, with accuracy depending on the experience of the operator, which 
has so far been limited by the rarity of the condition and the lack of training 
programs similar to those existing for the screening of fetal aneuploidies and 
fetal anatomical defects, such as congenital heart defects.  
 
PAS disorders are a growing obstetric issue and with the continuous increase 
in cesarean deliveries more studies are being published yearly. The definitive 
diagnosis, however, can only be made clinically at delivery and should be 
confirmed by histopathology wherever possible. This chapter reviews the 
various prenatal diagnostic techniques described in the international literature 
for the diagnosis of PAS disorders. As abnormal placentation is a spectrum 
disorder including both abnormal adherence (placenta creta) and abnormal 
invasion (placenta increta and placenta percreta), the term PAS disorders is 
used here as the overarching descriptor of the whole condition.  
 
2. Ultrasound imaging 
Different ultrasound imaging techniques have been used over the last 30 
years to diagnosis PAS disorders in the second and third trimesters of 
5 
 
pregnancy, including grey-scale and color Doppler imaging and/or three-
dimensional (3D) power Doppler sonography. A recent systematic review 
showed that since the first ultrasound descriptions of cases of PAS disorders 
in the early 1980s, 1078 cases including 38 case reports and 53 series have 
been reported in the international literature [15]. 
 
2.1. Ultrasound for the diagnosis of PAS disorders 
A systematic review and meta-analysis [9] of ultrasound studies involving 
3707 pregnancies at risk of PAS disorders found that the overall performance 
of ultrasound is excellent, with a sensitivity of 90.72% (95% CI; 87.2–93.6), 
specificity of 96.94% (95% CI, 96.3–97.5), and diagnostic odds ratio (DOR) of 
98.59 (95% CI, 48.8–199.0). A more recent systematic review and meta-
analysis of 14 cohort studies that included 3907 pregnancies presenting with 
placenta previa or low-lying placenta and one or more prior cesarean 
deliveries identified 328 (8.4%) cases of placenta previa accreta out of which 
298 (90.9%) were diagnosed prenatally by ultrasound [16]. The pooled 
performance of ultrasound for the prenatal detection of placenta previa 
accreta was higher in prospective than retrospective studies with DORs of 
228.5 (95% CI, 67.2–776.9) and 80.8 (95% CI, 13.0–501.4), respectively. 
 
2.2. The ultrasound signs 
The first ultrasound sign suggesting PAS disorders described by grey-scale 
ultrasound imaging was the “loss of the hypoechoic retroplacental (clear) 
zone,” which is thought to represent an abnormal extension of the placental 
villi through the decidua basalis into the myometrium [17]. The presence of 
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numerous large or irregular lacunae directly connected to a feeding vessel 
has also been repeatedly reported as a reliable grey-scale ultrasound sign 
[17,18]. However, throughout the literature the reported sensitivity of grey-
scale imaging ranges widely between 50% and 87% [9,16–19]. The 
incorporation of CDI has enabled better visualization of the uteroplacental 
circulation [9,16,17,20,21] and indicated that most cases of PAS disorders are 
associated with hypervascularization patterns (tornado vessels), within the 
placenta and between the placental basal plate or subplacental zone and 
underlying tissues (myometrium, bladder wall). The combination of grey-scale 
and color Doppler imaging ultrasound markers is reported to have increased 
the sensitivity of ultrasound imaging to around 90% with negative predictive 
values ranging between 95% and 98% [9].  
 
There is wide variation in prenatal detection rates depending on the 
ultrasound signs used (Table 1), operator’s experience, scanning conditions, 
equipment used, and gestational age. In particular, color Doppler imaging is 
more susceptible to operator error than grey-scale imaging. Differences in 
detection rates between studies can also be attributed to a combination of 
limited sample size, retrospective design, and variability of study inclusion 
criteria, and confirmation of diagnosis of PAS disorders at delivery and/or by 
histopathology [9,15,16]. In particular, as with all diagnostic techniques reliant 
on subjective opinion, the recorded presence or absence of each sign will be 
influenced by the operator’s interpretation of what constitutes that marker. 
This is particularly important for clinicians who may not have had much 
experience with ultrasonography of the placenta. Interestingly, the results of 
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well-conducted prospective cohort studies by Finberg and Williams [18] and 
Comstock et al. [21] indicate that the sensitivity and specificity of grey-scale 
imaging alone in screening for placenta previa accreta are high when 
performed by expert operators. 
 
In an attempt to reduce errors due to the subjectivity involved in making this 
diagnosis and ensure that all operators are using the same description for the 
same sign, the European Working Group on Abnormally Invasive Placenta 
(EW-AIP) recently proposed a standardized description and name for all the 
ultrasound signs used for the prenatal diagnosis of placenta accreta [12]. 
These are shown in Table 2. As the performance of each of the signs remains 
unclear from the published literature, an international expert group used the 
EW-AIP descriptors and a Delphi technique to generate a standardized pro 
forma for the minimum reporting requirements when performing an ultrasound 
assessment to diagnose PAS disorders [11]. A systematic review using this 
new standardized description for ultrasound examination of PAS disorders 
found that the loss of the clear zone (62.1%) and the presence of bridging 
vessels (71.4%) were the most common ultrasound signs found in cases of 
placenta creta. For placenta increta, a loss of the clear zone (84.6%) and 
subplacental hypervascularity (60%) were the most common ultrasound signs, 
whereas placental lacunae (82.4%) and subplacental hypervascularity 
(54.5%) were the most common ultrasound signs in placenta percreta [15]. 
 
Due to wide heterogeneity in terminology used to describe the grades of PAS 
disorders and differences in study design, no ultrasound sign or combination 
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of ultrasound signs is specific for the depth of accreta placentation [15-17]. In 
addition, accreta implantation is not homogeneous combining adherent and 
invasive villous tissue. Within this context, it would be pivotal that authors of 
prenatal diagnosis series should provide detailed data on the degree of depth 
villous invasion for each cases included in their study. It is also essential that 
future studies use standardized criteria for ultrasound imaging, clinical 
diagnosis and pathological examination to ensure good audit of clinical 
practice, research, improved teaching, and most importantly, better patient 
outcome.  
 
2.3. Models for improving ultrasound prediction 
A single-center retrospective cohort of 184 women with one or more prior 
cesarean deliveries and an ultrasound diagnosis of placenta previa or low-
lying placenta used linear logistic regression and multiparametric analyses to 
generate a predictive equation. The analysis was performed using a receiver 
operating characteristic (ROC) curve, which indicated that the combination of 
the smallest sagittal myometrial thickness, intraplacental lacunae, and 
bridging vessels, in addition to the number of previous cesarean deliveries 
and placental location, generates an area under the curve of 0.87 (95% CI, 
0.80–0.95) [22]. Each parameter was weighted to create a nine-point scale in 
which a score of 0–9 (placenta accreta index) provided a probability of 
invasion that ranged from 2%–96%, respectively. A similarly designed study 
of 92 cases of suspected accreta found that the area under the ROC curve 
was 0.85, with contribution from three variables: placenta previa, number of 
previous cesarean deliveries, and ultrasound suspicion [23]. These studies 
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indicate that combining diagnostic features associated with PAS disorders 
through mathematical modeling may improve accuracy of prenatal diagnosis 
compared with ultrasound alone. However, like most single center studies, 
these may have overestimated accuracy because they are conducted in 
centers specialized in prenatal diagnostics, and the overall number of cases 
of PAS disorders included in these series is small. The authors of both studies 
have also not differentiated between adherent and invasive cases in their 
series limiting the use of their data in clinical practice. In addition, the use of 
“morbidity adherent” to describe cases that are obviously invasive [22] is 
confusing and can lead to mis-interpretation of the data.  
 
2.4. Technical issues in the diagnosis of PAS disorders 
2.4.1. Transducer selection and approach 
The ultrasound signs of abnormal placental invasion are most often described 
in the literature using transabdominal scanning and only 6 out of 14 cohort 
studies of placenta previa accreta reported on the use of transvaginal 
scanning (TVS) [16]. TVS is often recommended to identify the cervical canal, 
internal os, and the relationship between the leading placental edge and the 
internal os; it can also be used for a focused evaluation of the lower uterine 
wall and the bladder interface. Transabdominal scans can be improved by 
selecting a higher frequency (5–9 MHz) transducer (linear if possible), and 
carefully “walking” the scar from one end to the other, keeping the transducer 
perpendicular to the uterine wall.  
 
2.4.2. Bladder filling 
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Ultrasound examination must be carried out with a full bladder (approximately 
200–300 mL). The bladder outline is vital to identify the lower uterine 
segment, which is the presumed location of the previous cesarean delivery 
scar, thereby making the assessment of the placental position in relation to 
the presumed site of the scar possible. Without a full bladder, such signs as 
bladder wall interruption, placental bulge, and uterovesical hypervascularity 
cannot be appropriately assessed [17]. 
 
2.4.3. Probe pressure 
Excessive probe pressure during transabdominal scanning can lead to the 
apparent loss of the retroplacental clear zone—one of the signs of invasive 
placentation. Therefore, this should be avoided. The loss of the retroplacental 
clear zone should be assessed with light probe pressure [17]. This pitfall is 
also much less likely to occur with TVS. 
 
2.4.4. Use of color flow mapping and power Doppler  
Excessive vascularity of the lower uterine segment is associated with 
abnormal invasion but is an inherently subjective sign. The normal 
uteroplacental interface is quite vascular but color Doppler imaging evaluation 
of this area is not part of a routine examination. Even experienced operators 
often do not have a baseline understanding of normal flow; it is, therefore, 
difficult to assess increased flow.  
 
Appropriate machine settings are essential [24]. This includes the correct gain 
setting for the individual woman, often referred to as the subnoise gain. This is 
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the gain value where any artifact just disappears on reducing the level. This 
individual setting allows for optimal visualization of the flow despite 
differences in tissue attenuation (e.g. between different amounts of abdominal 
adipose tissue). Likewise, the correct velocity scale is crucial to appropriate 
visualization of the vasculature: if too high, low flow will not be seen; if too low, 
an “aliasing” artifact will appear. Appropriate machine settings and a full 
awareness of how changes to these settings will affect the appearance of the 
vascularity are pivotal to avoid these pitfalls.  
 
3. The role of MRI in the diagnosis of PAS disorders 
MRI has been used increasingly for the prenatal diagnosis of PAS disorders 
[25–29]. The main MRI features of placenta accreta include abnormal uterine 
bulging, dark intraplacental bands on T2-weighted imaging, heterogeneous 
signal intensity within the placenta, disorganized placental vasculature, and 
disruption of the uteroplacental zone (Table 1). A recent systematic review 
found that most studies are of small sample size, and thus sensitivity and 
specificity of MRI in diagnosing accreta placentation varies widely between 
75% and 100% and 65% and 100%, respectively [28].  
 
Two systematic reviews and meta-analyses have found that the diagnostic 
value of ultrasound imaging and MRI in detecting placenta accreta is 
comparable. The first one published in 2013 [29] including 13 studies reported 
a sensitivity of 83% (95% CI, 77–88), specificity of 95% (95% CI, 93–96), and 
DOR of 63.41 (95% CI, 29.04–138.48) for ultrasound imaging compared with 
a sensitivity of 82% (95% CI, 72–90), specificity of 88% (95% CI, 81–94) and 
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DOR of 22.95 (95% CI, 3.19–165.11) for MRI. The second study [28] 
including 18 studies found that the overall diagnostic accuracy of MRI was a 
sensitivity of 94.4% (95% CI, 86.0–97.9), specificity of 84.0% (95% CI, 76.0–
89.8%), and DOR of 89.0 (95% CI, 22.8–348.1). The latter review also found 
that MRI has a high predictive accuracy in assessing both the depth and 
topography of placental invasion. It must be remembered that the MRI 
literature for prenatal detection of PAS disorders is biased because MRI is not 
a method used for screening. Only suspected cases are subjected to MRI 
examination.  
 
It has been suggested that MRI is particularly valuable for detecting [word 
added: OK?] parametrial invasion by villous tissue [26]. However, parametrial 
invasion is not commonly reported by other authors. MRI may be considered 
in cases with a posterior placenta and suspicion of accreta, e.g. history of 
prior instrumentation. Increased depth and fetal parts may preclude a 
complete ultrasound evaluation of the uteroplacental interface of a posterior 
placenta. MRI is unaffected by these factors [27].   
 
As the reported diagnostic performance of ultrasound imaging is so good in 
expert hands, it is debatable whether MRI can substantially add to the 
prenatal diagnosis of PAS disorders. Use of safe contrast agents may 
improve the diagnostic performance of MRI in the future.  
 
4. Prenatal screening for PAS disorders 
4.1. Clinical screening 
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Several risk factors for PAS disorders have been identified. These include 
advanced maternal age, multiparity, previous uterine surgery including 
curettage, assisted reproductive techniques, and previous cesarean delivery 
[19]. The most commonly described risk factor is the combination of previous 
cesarean delivery and placenta previa [30]. This combination also poses other 
problems, including increased risk of prenatal bleeding, access to the fetus for 
delivery, and the relatively poor contractility of the lower segment leading to 
greater postpartum blood loss.   
 
The prevalence of PAS disorders in the general population of pregnant 
women is around 1.7 per 10 000 pregnancies [30,31]. However, the incidence 
of placenta previa accreta is 4.1% in women with one prior cesarean delivery 
and 13.3% in women with two or more previous cesareans [16], and 
continues to rise with the number of prior cesareans [30]. Thus, focusing the 
screening of PAS disorders on this group is more productive in terms of 
diagnostic yield. All women found to have an anterior low-lying (placental 
edge <2 cm from the internal cervical os after 16 weeks of gestation) or 
placenta previa should be asked if they have had a previous cesarean 
delivery during prenatal consultations and, if they do, they should be referred 
to a center with expertise in the prenatal diagnosis of PAS disorders.  
 
4.2. Midpregnancy ultrasound screening 
Ultrasound screening for PAS disorders is not routinely taught during 
ultrasound training courses. Introducing such a screening program has been 
discussed but never implemented. We are not aware of ultrasound courses 
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that train ultrasonographers who perform routine midtrimester ultrasound for 
detailed fetal anatomy examination in screening for PAS disorders. 
Identification of an anterior low-lying placenta or an anterior previa or a 
placenta previa covering the internal os in a woman with a history of previous 
cesarean delivery should prompt referral to the most experienced operator 
available (preferably with expertise in diagnosis of PAS disorders) for a more 
detailed scan to look for signs. All sonographers should be aware of the risk of 
PAS disorders, especially with an anterior low placenta or placenta previa, 
and should be aware of the referral pathway for further investigation if they 
have any concerns. 
 
There are no prospective data on the ultrasound screening of PAS disorders 
at the routine midtrimester ultrasound examination by nonexpert operators 
[16]. Introducing such a screening program requires careful consideration, but 
is increasingly necessary owing to the constant rise in the number of 
cesarean deliveries. 
 
4.3. First trimester screening for PAS disorders 
Recently, it has been suggested that cesarean scar pregnancy represents a 
precursor of one of the different grades of PAS disorders [32–34]. 
 
Implantation of the gestational sac into a previous cesarean delivery scar is 
diagnosed using the following three criteria on TVS [35]:  
(1) Gestational sac located anteriorly at the level of the internal os within a 
visible myometrial defect (thin or absent myometrium) at the site of the 
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previous lower segment cesarean delivery scar. 
(2) Evidence of functional trophoblastic/placental circulation on color 
Doppler examination, characterized by high-velocity (peak velocity 
>20 cm/s) and low-impedance (pulsatility index <1) blood flow. 
(3) To distinguish from a spontaneous abortion in progress look for a 
negative “sliding organs sign,” defined as the inability to displace the 
gestational sac from its position at the level of the internal os using 
gentle pressure applied by the transvaginal probe.  
 
A recent systematic review and meta-analysis showed that cesarean scar 
pregnancy with positive embryonic/fetal heart activity managed expectantly is 
associated with a high burden of maternal morbidities including severe 
hemorrhage, early uterine rupture, hysterectomy, and severe PAS disorders 
[36]. However, this review included only 69 cases and thus there is still limited 
evidence on the natural history of cesarean scar pregnancy and in particular 
on the incidence of PAS disorders in women diagnosed with cesarean scar 
pregnancy in the first trimester of pregnancy.  
 
Overall, a cesarean scar pregnancy, even if not accreta, is associated with a 
very high risk of obstetric complications due to the consequences of a major 
placenta previa i.e. massive obstetric hemorrhage. Thus, women diagnosed in 
the first trimester with a cesarean scar pregnancy should be counselled 
regarding the high risk of complications including hysterectomy. Because of 
the high risk in continuing the pregnancy, treatment in the first trimester 
should be considered [37]. The most experienced operator available should 
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follow up the patient, preferably one with expertise in the diagnosis of PAS 
disorders. 
 
4.4. Biomarkers of PAS disorders 
Several placental and fetal hormones routinely used in the screening of 
Down’s syndrome have been found to have different concentrations in the 
serum of women with placenta previa accreta compared with those with a 
non-accreta previa [38–40]. At 11–12 weeks of pregnancy, human chorionic 
gonadotropin (hCG) and its free beta-subunit (b-hCG) are lower and 
pregnancy-associated plasma protein A (PAPP-A) is higher in the maternal 
serum of women with PAS disorders. By contrast, at 14–22 weeks, women 
presenting with a placenta previa are at higher risk of PAS disorders if serum 
b-hCG and alpha-fetoprotein (AFP) are above 2.5 multiples of the median 
(MoM) (OR 3.9; 95% CI, 1.5–9.9; and OR 8.3; 95% CI, 1.8–39.3, respectively) 
[41]. By contrast, no difference has been found in the amount of cell-free fetal 
DNA (cffDNA) in the maternal serum of women presenting with PAS disorders 
compared with normal controls [42]. Other biomarkers have been investigated 
retrospectively in the serum of women diagnosed with PAS disorders at 
delivery, but their lack of availability in hospital laboratories limits their use in 
clinical practice. Overall, biomarkers could be used with ultrasound imaging to 
screen for PAS disorders prenatally in a model similar to that used for 
aneuploidy screening; however, the benefit of this remains unknown until 
more prospective data are available.  
 
5. Limitations of prenatal diagnosis 
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One should remember that prenatal diagnosis of PAS disorders is not a 
histopathological diagnosis. Small areas of abnormal invasion have been 
reported even in asymptomatic women, and are of little clinical significance 
[43]. Similarly a simply adherent placenta will not require major surgery and 
can often be managed conservatively. In such cases, lack of ultrasound signs 
despite histopathological evidence of abnormal invasion may be interpreted 
as “failure” of prenatal diagnosis by ultrasound. It can be argued that the 
purpose of prenatal diagnosis is to forewarn the obstetric team of the 
probability of significant maternal morbidity. Therefore, the aim of prenatal 
imaging should be to detect PAS disorders of clinical significance such as 
placenta increta and percreta [10–12,15–17]. It is therefore paradoxical and 
confusing that an increasing number of authors of prenatal diagnostic series 
include in their cohort both superficially adherent and invasive placenta under 
the morbidly adherent [Ok to use this term here?] category. In addition, as 
many of these authors do not provide accurate clinical data on the differential 
diagnosis of the different categories of PAS disorders, it is difficult to separate 
retrospectively the noninvasive placenta accreta from the retained placenta. 
This has an impact on the epidemiology data and on determining the 
diagnostic accuracy of ultrasound and MRI. 
 
A significant proportion of cases of placenta previa are associated with PAS 
disorders, particularly if the uterus is scarred and the placenta is anterior 
and/or covering the cervix. Even if no villous tissue is invading the uterine 
myometrium, access to the fetus is complicated by the position of the 
underlying placenta, the lower uterine segment adjacent to the placenta is 
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highly vascularized, and major hemorrhage can still occur. It would be 
incorrect to believe that major morbidity should be expected only if prenatal 
diagnosis of PAS disorders has been made. 
 
It is also important to remember that although imaging is the best investigation 
modality available for prenatal identification of invasive placentation, the 
sensitivity and specificity are not 100%. In cases of false-negative prenatal 
diagnosis, the surgeon performing the cesarean delivery will use a low 
transverse uterine incision and this may lead to massive intraoperative 
hemorrhage, even before the fetus is delivered. By contrast, a false-positive 
diagnosis of PAS disorders will lead to an unnecessary midline vertical skin 
incision and a fundal uterine incision, thus increasing the risk of intraoperative 
and postoperative complications and the risk of PAS disorders and uterine 
rupture in subsequent pregnancies [16]. 
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Box 1. Recommendations for the evaluation of epidemiological data on placenta accreta 
spectrum (PAS) disorders. [Box 1 is not referred to in the manuscript itself. Please refer 
to it in brackets or in a full sentence in the most appropriate place] [Editor note: Re-
label as Table once placement determined] 
 
Recommendations Resource 
settings  
Quality of evidence 
and strength of 
recommendation 
Ultrasonography is a relatively inexpensive and widely 
available imaging modality and therefore should be the 
first line for the diagnosis of PAS disorders. 
All High and Strong 
Women diagnosed with cesarean scar pregnancy in the 
first trimester should be counselled regarding the high 
risk of requiring a hysterectomy owing to PAS disorders. 
They should be followed up by the most experienced 
operator available, preferably one with expertise in 
diagnosis of PAS disorders.  
All High and Strong 
At the mid-trimester examination for fetal anomaly, all 
women should be asked if they have had a previous 
cesarean delivery. If so, this should prompt careful 
assessment of the placental implantation site especially 
if it is anterior, low lying, or previa. 
All Medium and Strong 
The ultrasound signs observed for the diagnosis of PAS 
disorders should be described using standardized 
protocols. 
All Medium and Strong 
The recorded presence or absence of each ultrasound 
sign will be influenced by the operator’s interpretation of 
what constitutes that marker. 
All High and Strong 
MRI is not essential for making a prenatal diagnosis of 
suspected PAS disorders but may be useful in 
evaluating the pelvic extension of a placenta percreta or 
areas difficult to evaluate on ultrasound. 
High-
income 
Medium and Weak 
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Table 1 [Editor note: Renumber] 
Summary estimates of sensitivity and specificity of different ultrasound and MRI signs for the 
detection of PAS disordersa 
Detection signs Studies 
(n) 
Patients 
(n) 
% Sensitivity 
(95% CI) 
% Specificity 
(95% CI) 
Ultrasound signs     
   Placental lacunae 13 2725 77.4 
(70.1–83.1) 
95.02 
(94.1–95.8) 
   Loss of hypoechoic space 10 2633 66.2 
(58.3–73.6) 
95.8 
(94.9-96.5) 
   Abnormalities of uterus–
bladder interface 
9 2579 49.7 
(41.4–58.0) 
99.8 
(99.5–99.8) 
   Color Doppler abnormalities 12 714 90.8 
(85.2–94.7) 
87.7 
(84.6–90.4)  
MRI signs     
   Uterine bulging 5 119 79.1 
(60.3–90.4) 
90.2 
(76.2–96.4) 
    Heterogeneous signal 
intensity 
6 143 78.6 
(57.7–90.8) 
87.7 
(50.4–98.0) 
   Dark intraplacental bands on 
T2 
6 146 87.9 
(70.9–95.6) 
71.9 
(55.6–84.0) 
   Focal interruption of 
myometrium 
4 119 92.0 
(79.2–97.2) 
75.6 
(50.4–90.4) 
   Tenting of the bladder 2 74 80.0 
(28.0–99.5) 
98.6 
(92.2–100) 
a Adapted from D’Antonio et al. [9] and D’Antonio et al. [28]. 
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Table 2 [Editor note: Renumber] 
Unified descriptors (EW-AIP suggestions) for ultrasound findings in placenta accreta 
spectrum (PAS) disordersa 
Descriptor Finding 
2D grey-scale  
Loss of the “clear zone” Loss or irregularity of the hypoechoic plane in the myometrium 
underneath the placental bed (the “clear zone”) 
Abnormal placental 
lacunae 
Presence of numerous lacunae including some that are large and 
irregular (Finberg grade 3) often containing turbulent flow visible in 
grey-scale imaging 
Bladder wall interruption Loss or interruption of the bright bladder wall (the hyperechoic 
band or “line” between the uterine serosa and the bladder lumen) 
Myometrial thinning Thinning of the myometrium overlying the placenta to <1 mm or 
undetectable 
Placental bulge Deviation of the uterine serosa away from the expected plane, 
caused by an abnormal bulge of placental tissue into a 
neighboring organ, typically the bladder. The uterine serosa 
appears intact but the outline shape is distorted 
Focal exophytic mass Placental tissue seen breaking through the uterine serosa and 
extending beyond it. Most often seen inside a filled urinary bladder 
Color Doppler imaging  
Uterovesical 
hypervascularity 
Striking amount of color Doppler signal seen between the 
myometrium and the posterior wall of the bladder. This sign 
probably indicates numerous, closely packed, tortuous vessels in 
that region (demonstrating multi-directional flow and aliasing 
artifact). 
Subplacental 
hypervascularity 
Striking amount of color Doppler signal seen in the placental bed. 
This sign probably indicates numerous, closely packed, tortuous 
vessels in that region (demonstrating multidirectional flow and 
aliasing artifact) 
Bridging vessels Vessels appearing to extend from the placenta across the 
myometrium and beyond the serosa into the bladder or other 
organs. Often running perpendicular to the myometrium 
Placental lacunae 
feeder vessels 
Vessels with high velocity blood flow leading from the myometrium 
into the placental lacunae, causing turbulence upon entry 
3D intraplacental 
hypervascularity 
Complex, irregular arrangement of numerous placental vessels, 
exhibiting tortuous courses and varying calibers 
a Modified from Collins et al. [12]. 
